Coherus BioSciences to Participate at Upcoming November Investor Conferences
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Coherus BioSciences, Inc. announced that senior management will participate in several investor conferences, including Truist Securities BioPharma Symposium, UBS Biopharma Conference, and Evercore ISI HealthCONx Conference. The presentations will be webcasted and available on the Coherus website.
Positive
- None.
Negative
- None.
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:
- Truist Securities BioPharma Symposium In New York City on Wednesday, November 8, 2023, for 1x1 meetings only.
- UBS Biopharma Conference in Miami on Thursday, November 9, 2023, a fireside chat presentation at 11:30 a.m. Eastern Time will be webcast.
- 6th Annual Evercore ISI HealthCONx Conference in Miami on November 28-30, 2023, a fireside chat presentation on November 30th at 12:30 p.m. Eastern Time will be webcast.
A live audio webcast and an archive of the presentations from UBS Biopharma and Evercore ISI HealthCONx conferences will be available on the investors’ page of the Coherus website at http://investors.coherus.com.
Coherus Contact Information:
Jami Taylor
VP, Investor Relations
IR@coherus.com
FAQ
What conferences will Coherus BioSciences participate in?
Coherus BioSciences will participate in Truist Securities BioPharma Symposium, UBS Biopharma Conference, and Evercore ISI HealthCONx Conference.
Will the presentations be webcasted?
Yes, the presentations from the UBS Biopharma and Evercore ISI HealthCONx conferences will be webcasted.
Where can I access the webcasted presentations?
The webcasted presentations will be available on the investors' page of the Coherus website at http://investors.coherus.com.
What is the contact information for Coherus BioSciences?
The contact information for Coherus BioSciences is Jami Taylor, VP of Investor Relations, at IR@coherus.com.
Coherus BioSciences, Inc.
NASDAQ:CHRS
CHRS Rankings
CHRS Latest News
Apr 24, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 8, 2024
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS Stock Data
257.64M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
REDWOOD CITY
About CHRS
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp